Update of NICE Guidance PH18 on ‘Needle and syringe programmes’

PIEDs Review

Geoff Bates, Lisa Jones, Jim McVeigh
Contents
Glossary.............................................................................................................. 5
Abbreviations ..................................................................................................... 6
Executive summary ............................................................................................. 7
  Background ....................................................................................................... 7
  Objectives ......................................................................................................... 7
  Methods ............................................................................................................ 7
  Findings ............................................................................................................ 8
Summary of results ............................................................................................. 8
  What is the profile of PIED users and how do they differ from other IDUs? .... 8
  What impact does access to services have on the health and behaviour of PIED users? ................................................................. 8
  What influences the uptake of services amongst PIED users? ..................... 8
  How can services reach PIED users to raise awareness about a service and attract clients? ................................................................. 9
Discussion .......................................................................................................... 9
1  Introduction .................................................................................................... 11
  1.1  Aims and objectives .................................................................................. 11
  1.2  Research questions ................................................................................... 11
2  Background .................................................................................................... 12
  2.1  Previous NICE guidance ......................................................................... 12
  2.2  People who inject performance and image enhancing drugs ................. 12
  2.3  Findings from the previous evidence reviews ......................................... 13
3  Methods .......................................................................................................... 14
  3.1  Search strategy ......................................................................................... 14
  3.2  Electronic sources .................................................................................... 14
  3.3  Additional sources .................................................................................... 14
  3.4  Call for information ................................................................................ 15
  3.5  Inclusion and exclusion criteria ............................................................... 15
      3.5.1  Revised inclusion and exclusion criteria ......................................... 15
  3.6  Revised research questions ...................................................................... 15
  3.7  Data extraction and quality assessment ................................................... 15
Summary of evidence identified .................................................................................. 17
4.1 Summary of study identification ........................................................................ 17
4.2 Call for information ......................................................................................... 17
4.3 Study selection flow chart ................................................................................ 17

5 Findings .................................................................................................................. 18
5.1 Evidence identified through database searching and reference screening .......... 18
5.1.1 Overview of included studies ......................................................................... 18
5.1.2 Study aims and objectives .............................................................................. 18
5.2 Evidence identified through the call for information ......................................... 18
5.3 Quality assessment ............................................................................................. 19
5.3.1 Qualitative studies ......................................................................................... 19
5.3.2 Cross-sectional studies .................................................................................. 19
5.4 What is the profile of PIED users and how do they differ from other IDUs? ....... 19
5.4.1 Study participants’ method of PIED administration ...................................... 19
5.4.2 NSP use amongst study participants .............................................................. 20
5.4.3 Age ............................................................................................................... 20
5.4.4 Sexuality ....................................................................................................... 20
5.4.5 Sexual health behaviour ................................................................................ 21
5.4.6 Employment status ........................................................................................ 21
5.4.7 Injection risk behaviours .............................................................................. 21
5.4.8 Rates of BBV ................................................................................................. 21
5.5 What impact does access to services have on the health and behaviour of PIED users? ................................................................................................................. 21
5.5.1 Impact on needle disposal .............................................................................. 22
5.6 What influences the uptake of services amongst PIED users? ......................... 22
5.6.1 Service uptake amongst PIED users ............................................................. 22
5.6.2 Stigma associated with NSP attendance ...................................................... 23
5.6.3 Female PIED users ....................................................................................... 23
5.6.4 Range of services offered .............................................................................. 23
5.7 How can services reach PIED users to raise awareness about a service and attract clients? ............................................................................................................. 25
5.7.1 Promoting services in gyms .......................................................................... 25
5.7.2 Information seeking behaviour ................................................................. 25
5.7.3 Alternative settings in which to promote services .................................... 26
6 Discussion ........................................................................................................ 27
7 References ........................................................................................................ 29
  7.1 Included studies .......................................................................................... 29
  7.2 Excluded studies ......................................................................................... 29
  7.3 All other references .................................................................................... 35
Appendix 1. Example search strategy ................................................................. 37
Appendix 2. Inclusion and exclusion criteria ...................................................... 39
  Inclusion and exclusion criteria .................................................................... 39
  Types of studies ............................................................................................... 39
  Types of interventions .................................................................................... 39
  Types of participants ....................................................................................... 39
  Types of outcome measure ............................................................................ 39
Appendix 3. Evidence Tables ............................................................................ 41
Appendix 4. Quality Appraisal Checklist Tables .............................................. 48
### Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-Sectional Study</td>
<td>Examination of the relationship between disease and other variables of interest as they exist in a defined population at one particular time.</td>
</tr>
<tr>
<td>Drug schedule</td>
<td>Relates to the cycle or pattern of PIED use by a PIED drug user.</td>
</tr>
<tr>
<td>Harm reduction</td>
<td>Activities, interventions or techniques aimed at reducing the harms associated with unsafe drug use.</td>
</tr>
<tr>
<td>Injection Risk Behaviours</td>
<td>High risk behaviours related to injection drug use, such as receptive and distributive sharing, sharing paraphernalia and syringe re-use.</td>
</tr>
<tr>
<td>Needle disposal</td>
<td>Method of discarding of injecting equipment following use.</td>
</tr>
<tr>
<td>Safer injecting</td>
<td>A form of harm reduction relating specifically to injecting equipment, such as reducing needle sharing.</td>
</tr>
<tr>
<td>Stigma</td>
<td>An attribute or status that is generally seen as unacceptable that can lead to prejudice or discrimination.</td>
</tr>
</tbody>
</table>
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A&amp;E</td>
<td>Accident and emergency department</td>
</tr>
<tr>
<td>ACMD</td>
<td>Advisory Council on the Misuse of Drugs</td>
</tr>
<tr>
<td>BBV</td>
<td>Blood borne virus</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B virus</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>IDU</td>
<td>Injecting drug user</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NSP</td>
<td>Needle and syringe programme</td>
</tr>
<tr>
<td>PIEDs</td>
<td>Performance and image enhancing drugs</td>
</tr>
</tbody>
</table>
Executive summary

Background
Needle and syringe programmes (NSP) in England are based across a range of services including specialist services, pharmacies, outreach/mobile services, custody suites and A&E departments. In the UK, people who inject performance and image enhancing drugs (PIEDs), including steroids, growth hormone and other novel drugs, are believed to represent a significant and increasing proportion of all NSP users. PIED users are likely to have very different needs than other injecting drug users (IDUs). Following a review by NICE of NICE guidance on the optimal provision of NSP first issued in 2009 (National Institute for Health and Clinical Excellence, 2009), it was concluded that guidance regarding NSP provision for PIED users was required.

Objectives
The purpose of the review was to examine the evidence regarding the optimal provision of NSP for reducing the prevalence of blood borne viruses (BBVs) and morbidity and mortality relating to injecting drug use for people who PIEDs. The review aimed to examine effectiveness and cost-effectiveness data and views and perspectives regarding:

- The level of coverage of needles, syringes and other injecting equipment
- Types of NSP that are effective and cost-effective
- Additional harm reduction services offered by NSP

Methods
The methods of the effectiveness and cost-effectiveness review followed NICE protocols for the development of NICE Public Health Guidance. Eighteen databases were searched for effectiveness and cost-effectiveness studies published since 1990. All data extraction and quality assessment was undertaken by one reviewer and checked for accuracy by a second reviewer. Each study was also graded (+++, + or -) based on the extent to which the design and execution of the study minimised the potential sources of bias. Results of the data extraction and quality assessment for each study were presented as a narrative summary.

Due to the limited evidence identified, the objectives of the review were re-evaluated and changed to more broadly examine:

- The profile of PIED users
- The impact of services on health and behaviour
- Influences on the uptake of NSP services
- How NSP services can reach PIED users
Findings
One qualitative study and six studies based upon surveys were identified for inclusion in this review. Five studies were from the UK and two studies were from Australia. The qualitative study investigated experiences of and attitudes towards stigma in IDUs including four steroid injectors. Of the six studies based upon survey methodology, two studies investigated steroid use and adverse effects amongst steroid users and two studies primarily reported outcomes relating to risky injection behaviours and BBVs. One study examined the attitude of injecting steroid users towards factors associated with steroid use including media influence, masculinity and health outcomes. No cost-effectiveness studies were identified. Following a call for information, two unpublished reports evaluating a PIED clinic in Glasgow were identified, evidence from which was considered alongside the included studies.

Summary of results
What is the profile of PIED users and how do they differ from other IDUs?
Six studies included outcomes that help build a picture of the profile of PIED users. Evidence from one study suggested that PIED clients attending NSP are more likely to be male and younger in comparison to other IDUs. Across studies steroid users were likely to be aged between 26 and 32 years. Evidence from four studies suggested that the employment rate amongst steroid users is higher than the typical employment rate for other IDUs.

Two studies examined outcomes relating to injecting behaviour and BBV rates. One study reported lower rates of risky injecting behaviour and lower rates of HIV (0%) and HCV (10%) amongst steroid users in comparison to other IDUs. Two studies reported rates amongst steroid users of needle-sharing and needle re-use, and reported rates of BBV including HIV (12%), HCV (5%) and HBV (3%). One study reported low rates of condom use by steroid users with regular and casual partners.

What impact does access to services have on the health and behaviour of PIED users?
No studies were identified that examined the effectiveness of NSP provision on rates of HIV or other BBVs, or morbidity and mortality relating to injecting drug use in people who inject PIEDs. Evidence from one study suggested that some steroid users will use an NSP to dispose of needles, but that other disposal methods are preferred. Evidence from the unpublished evaluations of the Glasgow PIEDs clinic suggested that clinic attendance had benefits for safer injecting, reduced frequency of drug use, NSP attendance and diet and exercise.

What influences the uptake of services amongst PIED users
There was evidence suggesting that a high proportion of steroid users in Australia obtain needle and syringes from an NSP, and that steroid users in the UK have positive attitudes towards attending a free NSP. Unpublished evidence from the evaluation of the Glasgow PIEDs clinic suggested that the vast majority of clients were very satisfied with the clinic and
services provided. Evidence from one qualitative study suggested that stigma associated with attending NSP may be a barrier to steroid users accessing services. In one study it was reported that female steroid users believed a desirable service would include health checks and advice from health professionals as well as practical information about steroid use. Evidence from the Glasgow PIEDs clinic suggested that a desirable service may include PIED specific needle packs and offer services including blood testing and harm reduction advice including alternatives to PIED use, such as diet and exercise regimes.

How can services reach PIED users to raise awareness about a service and attract clients?
Six studies included outcomes relating to promoting services and information seeking behaviour. One study identified that female steroid users believe that advertising services in drug centres or gyms would attract clients, but one qualitative study reported that participants believed large gyms would not want to promote NSP due to the potential association of steroid use with that gym. Evidence across three studies suggested that steroid users know other steroid users and consider them a source of information about their drug use. The unpublished evaluations of the Glasgow PIEDs clinic revealed that gyms, a drugs centre and friends were all sources of information about the clinic for participants. Despite the service being widely advertised in gyms, surgeries, pharmacies and drug services the majority (62%) of participants had not seen any advertisements with the gym the most common location (37%).

Discussion
Over the last 20 years services providing NSP have observed a change in the profile of their clients, with increasing numbers of people identifying as users of steroids and other PIEDs attending such services. There is evidence that people who inject PIEDs use NSP differently to other client groups. They are likely to have different motivations for using drugs and different service needs and perceptions about services.

This review identified a distinct lack of literature on delivery of harm reduction services to people who inject PIEDs. In addition, all the research identified refers to steroid use and associated drugs, with no research identified in relation to users of other PIEDs (e.g. the melanotans). It has been recognised that people who inject PIEDs tend to be, but are not exclusively, male and generally of younger age. There is evidence of sharing and reusing needles and syringes and other injection equipment, suggesting that although people who inject PIEDs have a different risk profile to other people who inject drugs, they are nevertheless at a higher risk of infection than non-injectors.

There is an absence of published evidence on the impact of harm reduction services on the health and injection risk behaviours of people who inject PIEDs. However, there is some evidence to suggest that provision of NSP is desired in this population. Current service configurations, primarily structured to the needs of opiate and stimulant injectors, have been
shown to be a barrier to attendance by PIED injectors. Although based on a fragmented evidence base, the studies reviewed suggest that multi-faceted services are required to appeal to PIED injectors. Services should be PIED injector specific, and offer additional services alongside needle and syringe distribution such as advice and information, health expertise on diet and exercise, sexual health services, health monitoring including blood testing and vaccinations and information on high risk drugs and practices.

There was no evidence identified in this review that directly supports the existence of secondary exchange in this population, but studies suggest that PIED users see PIED using friends and acquaintances as a reliable source for the acquisition of and information about PIEDs.
1 Introduction

1.1 Aims and objectives
This review was undertaken to support the update of guidance on the optimal provision of needle and syringe programmes (NSP) for people who inject performance and image enhancing drugs (PIEDs). We adopted a broad perspective on the evidence examined, seeking to incorporate qualitative and quantitative evidence, examine successes and barriers to implementation, and assess the applicability and transferability of diverse evidence.

1.2 Research questions
For the review of quantitative evidence, the following key research questions were addressed:

1. What level of coverage of needles, syringes and other types of injecting equipment are most effective and cost-effective for reducing the prevalence of HIV and hepatitis C infection in people who inject PIEDs?

2. What types of NSP are effective and cost-effective for reducing the prevalence of HIV, hepatitis C and other blood-borne viruses (BBVs), and morbidity and mortality relating to injecting drug use in people who inject PIEDs?

3. Which additional harm reduction services offered by NSP are effective and cost-effective for reducing the prevalence of HIV, hepatitis C and other BBVs, and morbidity and mortality relating to injecting drug use in people who inject PIEDs?

For the review of qualitative evidence, the key research questions were, among people who inject PIEDs and practitioners involved in their care:

1. What do they identify as suitable types of NSP, and what do they believe to be a suitable level of coverage of needles, syringes and other types of injecting equipment?

2. What are their views and perspectives on, and experiences of, different types of NSP?

3. What are their views and perspectives on, and experiences of, additional harm reduction services offered by NSP?
2 Background

2.1 Previous NICE guidance

Needle and syringe programmes in England are based across a range of services including specialist services, pharmacies, outreach/mobile services, custody suites and A&E departments. NICE guidance on the optimal provision of NSP was first issued in February 2009 (National Institute for Health and Clinical Excellence, 2009). Prior to this a joint report by the Healthcare Commission and the NTA (Healthcare Commission/National Treatment Agency, 2008) had concluded that generally, pharmacy and specialist needle exchanges provided a wide range of harm reduction information and advice. However, the report also highlighted that there was a national shortfall in the provision of out-of-hours needle exchange, and that vaccination for hepatitis B (HBV), and testing and treatment for hepatitis C (HCV) was not provided widely enough by local drug treatment partnerships. The NICE guidance recommended that action was taken to increase access to and availability of sterile injecting equipment based on local needs. They also recommended that action was taken to increase the proportion of people with 100% coverage of sterile injecting equipment and the proportion of people from different groups of injecting drug users in contact with NSP. Areas were encouraged to provide a balanced mix of different levels of service and to coordinate services to ensure injecting equipment was available at all hours. The Advisory Council on the Misuse of Drugs (ACMD) report (2010a) on ‘The primary prevention of hepatitis C among injecting drug users’ was published concurrently with the NICE guidance and emphasised that on their own, NSP were insufficient to prevent hepatitis C, and that they should be commissioned as a component part of a comprehensive service. The report recommended that NSP provide or ensure access to a range of other services including HBV vaccination, referral to opiate substitution therapy, BBV antibody testing, and referral for HCV treatment. The impact of these policy developments on the commissioning and provision of NSP has yet to be reviewed but data on General Pharmaceutical Services in England shows a year on year increase on the number of community pharmacies in contract with PCTs to provide needle and syringe exchange; with an increase of 11% between 2009-10 and 2010-11 (The NHS Information Centre, 2011).

2.2 People who inject performance and image enhancing drugs

There is limited information available regarding the number of people using performance and image enhancing drugs (PIEDs). Only the use of anabolic steroids has been well documented, and their use has been shown to be relatively widespread with an estimated 70,000 people aged 16-59 year olds in England and Wales having used steroids in the past year (Home Office, 2012). Data from the UK suggests that the majority of users inject anabolic steroids (Advisory Council on the Misuse of Drugs, 2010b), putting them at risk of bacterial and fungal infections and the transmission of BBVs. While the risk of BBV transmission in anabolic steroid users has been suggested to be low compared to other
groups, such as those injecting opiates and stimulants, the practices and risks associated with the injection of anabolic steroids and other enhancement drugs remain poorly characterised (Evans-Brown et al., 2012). Evidence from a recent study reported rates of HIV (1.5%), exposure to HCV (5%) and exposure to HBV (9%) amongst PIED injectors (Hope et al., 2013). Further evidence suggests that PIED users may be more likely to have multiple sexual partners than non-IDUs and that condom use may be infrequent (Midgley et al., 2000).

Research from the UK has found that steroid users and users of other PIEDs may represent a significant proportion of NSP users (Lenehan et al., 1996). Between 1991 and 2006, the number of new steroid-injecting clients attending agency-based NSP in Merseyside and Cheshire increased seven-fold, whilst overall during this period there was a 2000% increase in the number of steroid injectors attending exchanges (Evans-Brown & McVeigh, 2008). There is evidence that steroid injectors use NSP differently to other client groups; making fewer visits per year and collecting large numbers of syringes in a single visit (McVeigh et al., 2003). Interviews with steroid injectors themselves indicate extensive peer distribution of injecting equipment (McVeigh et al., 2007).

In addition to anabolic steroids, in recent years injectable products for use as enhancement drugs have become increasingly available on the illicit market. An increasing range of drugs including insulin, growth hormone and novel drugs (such as those that stimulate secretion of growth hormone, IGF-1 and analogues, and Human Chorionic Gonadotrophin) are being injected to enhance physical performance (Evans-Brown et al., 2012). The melanotans, products that claim to contain melanotan II (and to a lesser extent melanotan I), are injected by users to get a cosmetic skin tan and, in the case of melanotan II and bremelanotide for their effects on sexual behaviour and function. Although the prevalence of use is not known, researchers have been alerted to their use in the general population through NSP seeking information after clients reported injecting these types of drugs (Evans-Brown et al., 2009a). It is not known how many people in the United Kingdom use drugs such as botulinum toxin or dermal fillers to treat wrinkles and lines but a number of factors suggest that there may considerable interest in these types of products among the general population (Evans-Brown et al., 2012).

2.3 Findings from the previous evidence reviews

The previous review of effectiveness and cost-effectiveness (Jones et al., 2008) identified 10 systematic reviews and meta-analyses, 24 primary studies and 13 economic evaluations for inclusion. The qualitative review (Cattan et al., 2008) identified 40 studies. The previous reviews found that there was limited evidence to determine the optimal provision of NSP, especially in a UK context, and that PIED users were underrepresented in the literature. Following a review of guidance PH18 by NICE it was concluded that guidance regarding NSP provision for PIED users was required, and it was agreed to develop supplementary guidance for this population.
3 Methods

3.1 Search strategy

The search approach taken for the reviews of effectiveness and cost-effectiveness was comprehensive and aimed to identify all the potentially relevant studies. All searches were conducted in accordance with the third edition of *Methods for the development of NICE public health guidance*.

3.2 Electronic sources

The following electronic sources were searched:

- ASSIA (Applied Social Science Index and Abstracts) via Proquest
- CINAHL (Cumulative Index of Nursing and Allied Health Literature) via EBSCOhost
- Cochrane Library via Wiley (CENTRAL, CDSR, DARE)
- EMBASE via NHS Evidence Health Information Resources
- EPPI Centre databases
- IBSS (international Bibliography of the Social Sciences) via Proquest
- MEDLINE via EBSCOhost
- PsycINFO via EBSCOhost
- Social Care Online via www.scie-socialcareonline.org.uk/
- Social Science Citation Index via Web of Science
- Sociological Abstracts via Proquest
- Sozial Medizin
- Sports Discus via EBSCOhost

The search strategy developed for the effectiveness review was adapted for use in the following major health economics databases:

- NHS Economic Evaluation Database (NHS EED)
- Health Economic Evaluation Database (HEED)
- EconLit via EBSCOhost
- EconPapers
- Tufts Cost-Effectiveness Analysis Registry

Search strategies were developed for each database using a combination of free text and thesaurus terms as appropriate. An example Medline strategy is presented in Appendix 1.

3.3 Additional sources

Further references were identified using a snowball approach whereby references of references and electronic citation tracking were used as a means of identifying further sources of evidence. A parallel call for information was also used as a means of identifying further sources of published and unpublished ('grey') literature. The snowballing technique incorporated searches of:

- Reference lists of retrieved articles meeting the inclusion criteria;
- Bibliographies of relevant literature;
- Key publications in the field;
- Reference lists of previous systematic reviews, review articles and other literature summaries; and
- Citation tracking tools e.g. the cited reference search tool on Web of Science.

Inclusion in the review was limited to English language studies and search limits were applied so that only studies published since 1990 were retrieved for screening.

3.4 Call for information
A joint call for information was sent out to researchers, practitioners and personal and institutional contacts known to the project team and to stakeholders registered with NICE. The call emphasised on the retrieval of unpublished data.

3.5 Inclusion and exclusion criteria
Two reviewers independently screened all titles and abstracts. Any discrepancies were resolved through discussion. Full titles of any titles/abstracts that were considered relevant by both reviewers were obtained for further screening. The relevance of each article was originally assessed according to pre-defined criteria (see Appendix 2). However, following screening it was apparent that very few if any studies would meet the full inclusion criteria.

3.5.1 Revised inclusion and exclusion criteria
Due to the limited amount of relevant data contained in the one study eligible for inclusion, it was not possible to answer the research questions identified for this review through any synthesis of the evidence. Following discussions between the researchers and NICE the inclusion criteria was broadened to allow the inclusion of studies that included a broader focus on PIED users and service provision.

3.6 Revised research questions
New research questions were developed to draw out evidence that will inform the provision of NSP to PIED users. There were four new research questions identified:

1. What is the profile of PIED users and how do they differ from other IDUs?
2. What impact does access to services have on the health and behaviour of PIED users?
3. What influences the uptake of services by PIED users?
4. How can services reach PIED users to raise awareness about a service and attract clients?

3.7 Data extraction and quality assessment
Data relating to both study design and quality were extracted by one reviewer into a predesigned table in Word. All extraction was independently checked for accuracy by a
second reviewer. The same reviewer who undertook the extraction assessed the quality of the individual studies and this was checked by a second reviewer for accuracy. Disagreements were resolved through discussion. A data extraction table was designed following the methods outlined in the *Methods for the development of NICE public health guidance*, further details of the information extracted is provided in Appendix 3.

The quality of the studies was assessed according to criteria set out in *Methods for the development of NICE public health guidance* (National Institute for Health and Clinical Excellence, 2012a). This information was tabulated (see Appendix 4) and summarised within the text of the report. Each study was graded using a code, ++, + or – based on the extent to which the potential sources of bias had been minimised, as outlined in the methods guide.
4 Summary of evidence identified

4.1 Summary of study identification
The database searches located 3,711 records. Following title and abstract screening, 76 references were identified as potentially relevant and eligible for further screening. In addition, three references were identified from the update review searches. Of these 79 references, 72 were available and screened against the revised inclusion and exclusion criteria. Of these, one qualitative study and five studies based upon surveys were considered eligible for inclusion. Through reference screening, one further study based upon survey data was identified that met the inclusion criteria and was included in the review. No cost-effectiveness studies were identified that met the inclusion criteria.

4.2 Call for information
Two unpublished reports were identified through the call for information. Evidence from these two evaluations of one PIED user clinic is presented throughout the findings, and used to build upon the published evidence in the seven studies identified through database searching and reference screening. Relevant findings from the two reports are reported in text boxes following the evidence from the identified studies under each heading.

4.3 Study selection flow chart

Figure 1. Flow chart of study selection process
5 Findings

5.1 Evidence identified through database searching and reference screening

5.1.1 Overview of included studies
In total, seven studies were identified that met the inclusion criteria for this review. This included one qualitative study (Simmonds & Coomber, 2009) and six studies based upon questionnaires and surveys carried out with PIED users (Burton, 1996; Day et al., 2008; Korkia et al., 1996; Larance et al., 2008; Lenehan et al., 1996; Walker & Joubert, 2011). Five of the studies were from the UK (Burton, 1996; Korkia et al., 1996; Lenehan et al., 1996; Simmonds & Coomber, 2009; Walker & Joubert, 2011) and two studies were Australian (Day et al., 2008; Larance et al., 2008).

5.1.2 Study aims and objectives
The qualitative study (Simmonds & Coomber, 2009) investigated experiences of and attitudes towards stigma in IDUs including four steroid injectors. Of the six studies based upon surveys, three studies (Burton, 1996; Korkia et al., 1996; Lenehan et al., 1996) investigated steroid use and adverse effects amongst steroid users. One study (Walker & Joubert, 2011) examined the attitudes of injecting steroid users towards factors associated with steroid use including media influence, masculinity and health outcomes, and two studies (Day et al., 2008; Larance et al., 2008) primarily reported outcomes relating to risky injection behaviours and BBV.

5.2 Evidence identified through the call for information
Two unpublished evaluations of the Glasgow PIEDs Clinic were sent to the review team following the call for information. This included an evaluation carried out in 2009 of service user attitudes towards and experiences of the Clinic, and a report providing an overview of one year of the Clinic from 1st April 2011-31st March 2012 including Clinic costs, and feedback concerning blood testing and other experiences in the Clinic.
5.3 Quality assessment

5.3.1 Qualitative studies
One study was based upon a qualitative design (Simmonds & Coomber, 2009) and was rated ‘+’ for quality. For this study the analysis was well reported and adequate, but the study was limited in particular by issues identified with context bias and methods, and lacked information about the role of the researchers and ethical issues.

5.3.2 Cross-sectional studies
Six studies were based upon survey data (Burton, 1996; Day et al., 2008, Korkia et al., 1996; Larance et al., 2008; Lenehan et al., 1996; Walker and Joubert, 2011) and were classed as having a cross-sectional design. Five of these studies were rated ‘+’ for quality (Burton, 1996; Korkia et al., 1996; Larance et al., 2008; Lenehan et al., 1996; Walker & Joubert, 2011) and one study was rated ‘-’ for quality (Day et al., 2008). All six studies were limited through the study design and reliance upon self-report data. For five studies rated ‘+’ for quality (Korkia et al., 1996; Larance et al., 2008; Lenehan et al., 1996; Walker & Joubert, 2011), study methodology suggested that the risk of bias was minimised across studies but the limitations due to study design meant that not all items on the quality checklist could be met. The study by Day and colleagues (2008) was a brief article reporting findings from the Australian NSP survey, and lacked detail throughout. In particular, the reporting of methods of analysis was inadequate in this study.

5.4 What is the profile of PIED users and how do they differ from other IDUs?

5.4.1 Study participants’ method of PIED administration
In four of the seven included studies (Day et al., 2008 [CS -], Larance et al., 2008 [CS +]) Simmonds & Coomber, 2009 [+]; Walker & Joubert, 2011 [CS +]) steroid using participants who all reported administering their steroids via injection. In three studies (Burton, 1996 [CS
participants included individuals who reported either injecting steroids or administering them orally.

5.4.2 NSP use amongst study participants
NSP use among participants varied by study; with two studies (Day et al., 2008 [CS -]; Walker & Joubert, 2011 [CS +]) including only participants who used NSP. In studies where participants were recruited from other settings, the use of NSP as a source of needles and syringes was reported to be high amongst participants in two studies (71%, Larance et al., 2008 [CS +]; ‘second highest source of needles’, Lenehan et al., 1996 [CS +]) but was not reported in two studies (Burton, 1996 [CS +]; Korkia et al., 1996 [CS +]). Evidence from the wider literature suggests that PIED users differ from other IDUs in their use of NSP. Analysis of NSP use in Cheshire and Merseyside suggests that steroid users make fewer visits per year to NSP than other IDUs, averaging approximately two visits per year (Beynon et al., 2007, McVeigh et al., 2003).

5.4.3 Age
Evidence from the one study, that included male and female NSP users, suggests that the vast majority of PIED users attending NSP are male, and that as a proportion of clients, PIED users are more likely to be male than other drug users (Day et al., 2008 [CS -]). PIED clients attending NSP were reported to be younger (mean age 27 years) than other IDUs (mean age 30 years). In four further studies that reported mean age of PIED users (Korkia et al., 1996 [CS +]; Larance et al., 2008 [CS +]; Lenehan et al., 1996 [CS +]; Simmonds & Coomber, 2009 [+]) participants were between 28 and 32 years, and in one study (Walker & Joubert, 2011 [CS +]) the most frequent age group for NSP using participants was 26-30 years. However, one study (Burton, 1996 [CS +]), which investigated the age at which participants first used steroids, reported that the majority (61%) had first used steroids before the age of 20. This might suggest that PIED users start using PIEDs earlier in life and only come in to contact with services once they are established users.

Case study: evidence from the Glasgow PIEDs Clinic
In one year at the Glasgow PIEDs Clinic (1st April 2011 – 31st March 2012) there were 400 transactions at the clinic with 284 clients. The majority of clients were male (97%) and aged between 20 and 35 (77%). A small number of clients were aged 15-19 (1%).

5.4.4 Sexuality
Evidence from one study (Larance et al., 2008 [CS +]) suggested that gay and bisexual PIED using men were less likely to access an NSP to acquire equipment than heterosexuals, although it was not clear why this is the case. Day and colleagues (2008 [CS -]) reported that steroid injectors using NSP were more likely to be heterosexual than other IDUs.
5.4.5 Sexual health behaviour
Burton (1996 [CS +]) examined condom use amongst steroid users in Wales. The majority of participants never used condoms with a regular partner (78%) or with a casual partner (62%), with one quarter (24%) reporting using a condom “always”, “often” or “sometimes” with a casual partner.

5.4.6 Employment status
Evidence from one study (Simmonds & Coomber, 2009 [+]) suggested that rates of employment are greater in PIED users than other IDUs, which could impact on this population’s ability to access NSP during the day. Lenehan and colleagues (1996 [CS +]) and Burton (1996 [CS +]) reported low unemployment rates (89%, 94% respectively) amongst steroid users and Koria and colleagues (1996 [CS +]) reported high employment rates amongst female steroid users (73% in full or part time work, or self-employed).

5.4.7 Injection risk behaviours
Three studies reported outcomes relating to risky injecting behaviour (Burton, 1996 [CS +]; Day et al., 2008 [CS -]; Larance et al., 2008 [CS +]). Day and colleagues (2008[CS -]) examined differences in injecting behaviour between steroid users and other IDUs, and reported that steroid users report less needle sharing (OR 0.18, 95% CI 0.09-0.36) and less frequent injecting (OR 0.14, 95% CI 0.10-0.19). Larance and colleagues (2008 [CS +]) and Burton (1996 [CS +]) reported rates of needle sharing ever amongst PIED users (5%, 16% respectively) and of needle re-use (13%, 37%). A higher proportion of PIED users reported ever sharing other injecting equipment including bladders or vials¹ in the same two studies (29%, 59% respectively). A 2010 report by the ACMD details needle sharing rates amongst PIED users as being between 0% and 20% across studies in the UK, and rates of reuse slightly higher at 4%-37% (Advisory Council on the Misuse of Drugs, 2010b).

5.4.8 Rates of BBV
Two studies examined rates of BBV amongst PIED users (Day et al., 2008 [CS -]; Larance et al., 2008 [CS +]). Larance and colleagues (2008 [CS +]) report that of their steroid using participants, 3% were HBV positive, 5% HCV positive and 12% HIV positive. Day and colleagues (2008 [CS -]) report that in their survey no steroid injectors were HIV positive and 10% were HCV positive, which was a lower proportion than in other injecting drug users (OR 0.10, 95% CI 0.07-0.15). In the same study steroid users were less likely than other IDUs to have been screened for HCV (OR 0.17, 95% CI 0.13-0.22) and HIV (OR 0.21, 95% CI 0.17-0.26).

5.5 What impact does access to services have on the health and behaviour of PIED users?
No studies were identified that examined the effectiveness of NSP provision in terms of impact on rates of HIV or other BBV or morbidity and mortality relating to injecting drug use

¹ Containers used for the storage of drugs that can be drawn out with a needle or syringe.
in people who inject PIEDs. Consequently there is an absense of published evidence on the impact of services on the health and behaviour of PIED users. However, there was evidence from one study (Burton, 1996 [CS +]) on the impact of NSP provision on needle disposal behaviours.

5.5.1 Impact on needle disposal
Analysis of methods of needle disposal in one study (Burton, 1996 [CS +]) found that one quarter (26%) of survey respondents reported using NSP for this activity, with more frequent methods of disposal including using a dustbin (37%) and passing the equipment on to someone else (34%).

Case study: evidence from the Glasgow PIEDs Clinic
Findings from the 2009 report of the impact of the Glasgow PIEDs clinic suggested clinic attendance had positive impacts on safer injecting practices (72%), frequency of drug use (55%) and clients' diet and exercise regimes (59%). Some clients may have decided against injecting steroids following harm reduction discussions, and appeared to make changes to their diet and exercise regimes as an alternative. Use of pharmacy needle exchange increased from 35% to 70% of respondents following a visit to the clinic.

5.6 What influences the uptake of services amongst PIED users?
5.6.1 Service uptake amongst PIED users
Data from the wider literature suggests that NSP clients in Merseyside and Cheshire, where monitoring of steroid user attendance has been in place since the 1990s, include a large proportion of steroid users (Beynon et al., 2007). It is reported that attendance at NSP in this population has greatly increased over the past 20 years (Advisory Council on the Misuse of Drugs, 2010b). Evidence from one study in the North West of England (Lenehan et al., 1996 [CS +]) suggests that the vast majority of participants (92%) would attend a free NSP for steroid users. This suggests that the provision of services for PIED users is desired in this population and the availability of services supports this: the ACMD identified four examples of services for PIED users in the annexes to their 2010 report (Advisory Council on the Misuse of Drugs, 2010c). Services included the Drugs in Sport Clinic and Users' Support in Durham, the Wirral Harm Reduction Service, Smart Muscle in London and the Surrey Harm Reduction Outreach Service. There was evidence from one study in Australia of NSP use amongst steroid users, with 71% participants obtaining needles and syringes from an NSP but only 7% reported seeking information from the same service (Larance et al., 2008 [CS +]).
5.6.2 Stigma associated with NSP attendance

One study included outcomes relating to the attitudes of PIED users towards NSP. One qualitative study of four PIED users (Simmonds & Coomber, 2009 [+]) reported that stigma associated with attending an NSP may be a barrier for this population to accessing services. Steroid users distanced themselves from other IDUs and wanted to be recognised as a steroid user by both other IDUs and health professionals. Steroid users were concerned about being mistaken for street drug using IDUs; they saw themselves as being very separate to that population and did not want to be connected with the negative assumptions associated with IDUs. Burton (1996 [CS +]) suggests that participant survey responses “perceived themselves as being different to stereotypical drug users” but did not elaborate upon this finding in the article.

5.6.3 Female PIED users

It is likely that male and female PIED users’ needs are likely to differ due to gender specific barriers and stigmatization associated with the use of PIEDs (ACMD, 2010b) and differing side effects and consequences of PIED use for males and females (Burton, 1996 [CS +]; Lenehan et al., 1996 [CS +]). One study (Korkia et al., 1996 [CS +]) examined attitudes of female PIED users towards desirable services. Korkia and colleagues (1996 [CS +]) reported that female PIED users believed that a desirable service would include both health checks and advice provided by health professionals and practical information about PIED use.

5.6.4 Range of services offered

In one study, not formally included in this review, Pates and Barry (1996)2 reported that advice, testing for counterfeit samples and blood testing were all mentioned by steroid users in Cardiff as being help they would like to receive. Articles in the wider literature suggest that adulteration and contamination of PIEDs is likely to be commonplace (Evans-Brown et al., 2009b; McVeigh et al., 2012) and offering testing of PIEDs or information and advice on products may be useful for clients who are purchasing products illegally or over the internet.

---

2 There was insufficient detail within the study relating to the research questions identified for this review for the study to be included.

---

Case study: evidence from the Glasgow PIEDs Clinic

In the 2009 survey clients reported positive feedback about the clinic with the vast majority of clients “very satisfied” with the service (93%) and rating the advice they received at the clinic as “very good” (88%) and helpful (94%). All but one client (98%) stated they would or had already used the service again and all clients (100%) stated that they would recommend the clinic to friends.
Case study: evidence from the Glasgow PIEDs Clinic

The 2009 and 2012 reports into the Glasgow PIEDs Clinic examined four areas of services that the Clinic provided to clients: PIED specific needle packs, blood testing, harm reduction advice and information and referral on to other services.

Needle packs

Needle packs provided by pharmacies to IDUs may be opiate specific, which may be a barrier to uptake of this service by PIED users (see discussion of stigma in 6.6.2). A typical pharmacy needle pack includes equipment for the injection of opiates such as citric acid and spoons and opiate specific information that is not relevant to PIED users and their needs. A specific PIED user needle pack is available at the Glasgow PIEDs clinic containing needles and safer injecting information in a discreet case. The 2009 survey of clinic users provided positive feedback, with over 3/4 (77%) participants saying they liked the packs. Other options are available at the Clinic for clients for whose needs the new pack does not meet.

Blood testing

Feedback from PIED users in 2009 suggested that amongst those who had not used the clinic, the vast majority (80-90%) stated that they would be more likely to attend the clinic if blood testing was offered for health conditions commonly associated with PIED use including cholesterol, liver function tests and testosterone levels. Subsequently, blood testing was introduced to the clinic and is offered to clients for analysis of conditions where risk may increase due to PIED use including BBV, liver function, kidney function, hormone levels and cholesterol. In the 2012 report it was reported that between August 2011 and March 2012 there were 36 cases of blood testing at the clinic which revealed zero cases of BBV, 31 (86%) abnormal hormone results, 14 (39%) abnormal liver results, 8 (22%) abnormal cholesterol results and 7 (19%) abnormal kidney results.

Harm reduction advice

Clients receive harm reduction advice to promote safer injecting practices and alternatives to PIED use through making changes to diet and exercise. Some clients were reported to take away only the personalised diet and exercise plans rather than any injecting equipment including nearly one third (29%) of clients over one three month period. Dawson (2001) suggests that harm reduction for PIED users should include advice on training and diet to promote behavioural changes as an alternative to PIED use.

Referral to other services

Discussions between Clinic staff, the client and a nurse take place about health issues that clients present at the Clinic with. This includes injury or side effects related to injection of PIEDs such as infected abscess, deep vein thrombosis and steroid acne. Referral is made to additional services where necessary.
This evidence suggests that multi-faceted PIED specific services that offer services such as advice and information, health expertise, testing for contaminants and blood testing may appeal to PIED users. The UK PIED services identified in 5.6.1 typically offered a variety of services for PIED users including testing for BBV, vaccination for hepatitis A and B, sexual health screening, referral to other services where necessary, advice on diet and training, practical advice regarding the use of steroids and harm reduction (Advisory Council on the Misuse of Drugs, 2010c).

5.7 How can services reach PIED users to raise awareness about a service and attract clients?

There was evidence from six studies relating to sources of information regarding PIED use, including beliefs about promoting PIED services and where PIED users acquired information.

5.7.1 Promoting services in gyms

Korkia and colleagues (1996 [CS +]) reported suggestions by female steroid users to use a local drugs centre or advertising in gyms to attract clients to a service. In their qualitative study, Simmonds and Coomber (2009 [+]) reported a belief amongst the four participants that large gyms might not want to promote needle exchange due to the association with steroid use in that gym.

5.7.2 Information seeking behaviour

There is evidence that PIED users actively seek information relating to their drug use, but the evidence in three studies (Burton, 1996 [CS +]; Larance et al., 2008 [CS +]; Lenehan et al., 1996 [CS +]) is mixed as to where this information seeking takes place. In the study of steroid users in Sydney (Larance et al., 2008 [CS +]), fewer participants reported their gym as a source of information (18%) with more participants seeking information from the internet (62%), friends (55%) and doctors (22%). Lenehan and colleagues (1996 [CS +]) reported that 43% of steroid using participants in their study in North West England had sought advice from a doctor about medical issues relating to their drug use. Burton (1996 [CS +]) however reported that just one participant in that study had used their GP as a source of information, with friends (57%), books and magazines (28%) and gym owners (11%) more frequently used. It is unknown however whether the increasing accessibility of information on the internet would impact upon these participants’ information seeking.

Walker and Joubert (2011 [CS +]) state that the vast majority (93%) of steroid NSP users who responded to their survey knew at least one other steroid user, while two fifths (42%) knew 10-12 users. The authors also report that all but one participant (98%) trusted their source of steroids with one third (34%) of participants’ source being someone at their gym.
5.7.3 Alternative settings in which to promote services

The 2010 ACMD report states that settings in which to engage steroid users in harm reduction could include primary care settings such as outreach services in gyms, NSP, pharmacies and GP surgeries (Advisory Council on the Misuse of Drugs, 2010b). The evidence reported here suggests that PIED users use these settings as a source of information, but that efforts to promote services and reach more PIED users may need to include tapping into resources such as the internet and peer networks.

Case study: evidence from the Glasgow PIEDs Clinic

The 2009 survey of the Glasgow PIEDs Clinic revealed that four in ten participants using the Clinic (41%) heard about the Clinic at the gym. One third (33%) learned about the Clinic at the city’s Crisis Drugs Centre and one quarter (23%) from a friend. The survey revealed that six in ten participants (62%) had not seen a poster for the Clinic despite it being widely advertised in gyms, doctor’s surgeries, pharmacies and drug services. Of those who had seen the Clinic advertised, the gym was the most common location (37%).
6 Discussion

This review examined evidence on the optimal provision of NSP to people who inject PIEDs. NSP are a fundamental component of harm reduction services and provide access to sterile injection equipment for people who inject drugs. Primarily developed as a preventative measure for the spread of HIV among people who inject opiates and stimulant drugs (so called ‘street drugs’) over the last 20 years services providing NSP have observed a change in the profile of their clients, with increasing numbers of people identifying as users of steroids and other PIEDs attending such services. There is evidence that people who inject PIEDs use NSP differently to other client groups. They are likely to have different motivations for using drugs and different service needs and perceptions about services. As such there is a need to identify how best to deliver services to this population.

This review identified a distinct lack of literature on delivery of harm reduction services to people who inject PIEDs. In addition, all the research identified refers to steroid use and associated drugs, with no research identified in relation to users of other PIEDs (e.g. the melanotans). It has been recognised that people who inject PIEDs tend to be, but are not exclusively, male and generally of younger age. In comparison to people who inject opiates and stimulants, injection risk behaviours have been less extensively explored among people who inject PIEDs; with estimates of needle and syringe sharing varying between 0 and 20% across UK studies. There is evidence of sharing and reusing needles and syringes and other injection equipment, suggesting that although people who inject PIEDs have a different risk profile to other people who inject drugs, they are nevertheless at a higher risk of infection than non-injectors. There is some evidence available that PIED users engage in risky sexual behaviours (Baron, 1996; Midgley et al., 2000; Hope et al., 2013), and there may be a need to increase PIED user engagement with sexual health services.

There is an absence of published evidence on the impact of harm reduction services on the health and injection risk behaviours of people who inject PIEDs. However, there is some evidence to suggest that provision of NSP is desired in this population. Current service configurations, primarily structured to the needs of opiate and stimulant injectors, have been shown to be a barrier to attendance by PIED injectors. Studies suggest that PIED injectors perceive themselves to be separate to other population of PWIDs and wish to avoid such associations, which they perceive negatively. Although based on a fragmented evidence base, the studies reviewed suggest that multi-faceted services are required to appeal to PIED injectors. Services should be PIED injector specific, and offer additional services alongside needle and syringe distribution such as advice and information, health expertise on diet and exercise, sexual health services, health monitoring including blood testing and vaccinations and information on high risk drugs and practices.

During consultation on the public health guidance PH18, secondary exchange amongst PIED users was highlighted as being an opportunity to promote the safe distribution of
injecting equipment through peer networks (National Institute for Health and Clinical Excellence, 2012b). There was no evidence identified in this review that directly supports the existence of secondary exchange in this population, but studies suggest that PIED users see PIED using friends and acquaintances as a reliable source for the acquisition of and information about PIEDs. Additionally, examination of the number of syringes taken from NSP in Merseyside and Cheshire (McVeigh et al., 2003) has revealed that in 16.5% of transactions with steroid users in one year between 100 and 1000 syringes have been provided. This suggests that secondary exchange amongst PIED users may be viable and already on going, but more research is needed to examine how to utilise these networks to promote safer injecting behaviours and harm reduction services.
7 References

7.1 Included studies


7.2 Excluded studies


Dobbins, B. (1996). "Steroids are they heaven...or are they hell?" Joe Weider's Muscle & Fitness 57(10): 106.


Gordon, D. (2002). "It's a botox blast: are dangers getting overlooked as we flock to the needle?" Men's Fitness 18(9): 78-79.


7.3 All other references


### Appendix 1. Example search strategy

<table>
<thead>
<tr>
<th>#</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>exp Needle-Exchange Programs/</td>
</tr>
<tr>
<td>2</td>
<td>((needle* or syringe* or inject*) adj3 exchange).tw.</td>
</tr>
<tr>
<td>3</td>
<td>shooting galler*.tw.</td>
</tr>
<tr>
<td>4</td>
<td>harm reduction/</td>
</tr>
<tr>
<td>5</td>
<td>(harm adj reduc*).tw.</td>
</tr>
<tr>
<td>6</td>
<td>or/1-5</td>
</tr>
<tr>
<td>7</td>
<td>((needle* or syringe* or inject* or citric acid* or foil or steril* or bleach* or disinfect*) adj3 (suppl* or access* or provision or provid* or distribut* or dispens* or pack*)).tw.</td>
</tr>
<tr>
<td>8</td>
<td>((needle* or syringe* or inject*) adj3 (program* or service* or center* or centre* or scheme* or facility or facilities or area* or prison* or pharmacy or pharmacies or unit or units or room*)).tw.</td>
</tr>
<tr>
<td>9</td>
<td>((needle* or syringe* or inject*) and (steril* or bleach* or disinfect* or clean* or safe*)).tw.</td>
</tr>
<tr>
<td>10</td>
<td>(nsp or nep or nsep or nsps or nep or nseps or sep or seps).tw.</td>
</tr>
<tr>
<td>11</td>
<td>or/7-10</td>
</tr>
<tr>
<td>12</td>
<td>((needle* or syringe* or inject* or slot or dispensing or vending) adj3 (machine* or (peer adj distrib*)).tw.</td>
</tr>
<tr>
<td>13</td>
<td>(electronic adj dispens*).tw.</td>
</tr>
<tr>
<td>14</td>
<td>((needle* or syringe* or inject* or sharps or cin or &quot;drug-related litter&quot;) adj3 (dispos* or bin* or container*)).tw.</td>
</tr>
<tr>
<td>15</td>
<td>(disposal adj3 (bin* or container* or safe*).tw.</td>
</tr>
<tr>
<td>16</td>
<td>(fitpack* or distribox* or steribox* or fitbin* or (drop adj box*)).tw.</td>
</tr>
<tr>
<td>17</td>
<td>or/12-16</td>
</tr>
<tr>
<td>18</td>
<td>Risk-taking/</td>
</tr>
<tr>
<td>19</td>
<td>(risk* adj3 behavio*?).tw.</td>
</tr>
<tr>
<td>20</td>
<td>(inject* adj3 (behaviour* or behavior* or practic* or pattern* or risk* or unsafe* or harm* or hazard* or frequenc*)).tw.</td>
</tr>
<tr>
<td>21</td>
<td>Needle Sharing/</td>
</tr>
<tr>
<td>22</td>
<td>((needle* or syringe* inject*) adj3 (sharing or share* or reusing or reuse* or re-using or re-use or return*).tw.</td>
</tr>
<tr>
<td>23</td>
<td>or/18-22</td>
</tr>
<tr>
<td>24</td>
<td>6 or 11 or 17 or 23</td>
</tr>
<tr>
<td>25</td>
<td>Performance-Enhancing Substances/</td>
</tr>
<tr>
<td>26</td>
<td>(PIED or PIEDs).tw.</td>
</tr>
<tr>
<td>27</td>
<td>((performance OR image) adj5 drug*).tw.</td>
</tr>
<tr>
<td>28</td>
<td>Steroids/</td>
</tr>
<tr>
<td>29</td>
<td>Anabolic agents/</td>
</tr>
<tr>
<td>30</td>
<td>((anabolic or androgenic) adj4 (steroid* or agent*).tw.</td>
</tr>
<tr>
<td>31</td>
<td>ergogenic.tw.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>32</td>
<td>Doping in Sports/</td>
</tr>
<tr>
<td>33</td>
<td>Human Growth Hormone/</td>
</tr>
<tr>
<td>34</td>
<td>Growth Hormone-Releasing Hormone/</td>
</tr>
<tr>
<td>35</td>
<td>(growth hormone or HGH).tw.</td>
</tr>
<tr>
<td>36</td>
<td>alpha-MSH/</td>
</tr>
<tr>
<td>37</td>
<td>(melanotan or bremelanotide).tw.</td>
</tr>
<tr>
<td>38</td>
<td>(dermal filler* or cosmetic filler*).tw.</td>
</tr>
<tr>
<td>39</td>
<td>or/25-38</td>
</tr>
<tr>
<td>40</td>
<td>exp Botulinum Toxins/</td>
</tr>
<tr>
<td>41</td>
<td>(botulinum or botox).tw.</td>
</tr>
<tr>
<td>42</td>
<td>Beauty/ or Beauty Culture/ or Cosmetics/ or Cosmetic Techniques/ or Skin Aging/ or Rejuvenation/ or Facial Expression/</td>
</tr>
<tr>
<td>43</td>
<td>(cosmetic* or beaut* or wrinkle* or aesthetic* or esthetic* or face* or facial* or image*).tw.</td>
</tr>
<tr>
<td>44</td>
<td>(40 OR 41) AND (42 OR 43)</td>
</tr>
<tr>
<td>45</td>
<td>39 OR 44</td>
</tr>
<tr>
<td>46</td>
<td>24 AND 45</td>
</tr>
<tr>
<td>47</td>
<td>animals/ not humans/</td>
</tr>
<tr>
<td>48</td>
<td>46 NOT 47</td>
</tr>
<tr>
<td>49</td>
<td>limit 48 to yr=1990-current</td>
</tr>
</tbody>
</table>
Appendix 2. Inclusion and exclusion criteria

Inclusion and exclusion criteria
Two reviewers will independently screen all titles and abstracts. Full titles of any titles/abstracts that are considered relevant by both reviewers will be obtained for further screening. The relevance of each article will be assessed according to the criteria set out below. Any discrepancies will be resolved by consensus or, if necessary, by consulting a third reviewer.

Types of studies
For the assessment of effectiveness; good quality systematic reviews of experimental and observational studies, randomised controlled trials, controlled non-randomised studies, controlled and uncontrolled before and after studies, cross-sectional studies, cohort studies, case-control studies and ecological studies. For the assessment of cost-effectiveness; economic evaluations conducted alongside trials, modelling studies and analyses of administrative databases. Only full economic evaluations that compare two or more options and consider both costs and consequences (including cost-effectiveness, cost-utility and cost-benefit analyses) will be eligible.

For the review of qualitative literature; studies of any qualitative design will considered for inclusion, for example, ethnographic studies, studies that use a phenomenological or grounded theory approach, or participatory action research. For studies based on mixed methods research, both the qualitative and quantitative elements will be screened for inclusion.

Types of interventions
Interventions involving the supply of needles, syringes and other injecting equipment (e.g. filters, mixing containers and sterile water) and harm reduction interventions provided by NSP will be eligible.

Types of participants
People who currently inject non-prescribed anabolic steroids and other performance and image enhancing drugs (PIEDs). Inclusion of studies in the review will be based on a broad definition of injectable enhancement drugs that takes into account their range of uses for both enhancement and self-treatment of medical problems.

Types of outcome measure
Qualitative studies of relevance include those on the views, experiences and attitudes of people who inject PIEDs in relation to the supply of needles, syringes and other injecting equipment through NSP and harm reduction interventions delivered via NSP. In addition to views and experiences, studies of perspectives on barriers to, and opportunities for, changing behaviour in relation to PIED use in the context of NSP are also of relevance.
For effectiveness studies, those reporting changes in behaviour relating to injecting drug use will be eligible, including:

- Incidence and prevalence of blood-borne viral infections, primarily HIV and hepatitis C, but also hepatitis B;
- Morbidity and mortality relating to PIED use, e.g. injecting site bacterial infections;
- Self-reported injecting risk-behaviour (e.g. sharing or re-using injection equipment, frequency of injection);
- Additional outcomes of interest will include utilisation of other health care services.

For cost-effectiveness studies, those reporting both costs (regardless of how estimated) and outcomes (regardless of how specified) will be eligible. Outcomes of interest are likely to include, but will not be limited to:

- incremental costs per case of HIV infection prevented
- incremental costs per case of hepatitis C infection prevented
- incremental costs per additional QALY gained
### Appendix 3. Evidence Tables

<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burton, 1996</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Country:</strong></td>
<td><strong>UK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Funding source:</strong></td>
<td>Clwyd social services department</td>
<td></td>
</tr>
<tr>
<td><strong>Entry criteria:</strong></td>
<td>Anabolic steroid users recruited through gyms</td>
<td><strong>Profile of service users</strong></td>
</tr>
<tr>
<td><strong>Participant characteristics:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number of participants:</strong></td>
<td>70</td>
<td><strong>First used AS:</strong></td>
</tr>
<tr>
<td><strong>Males (%):</strong></td>
<td>62 (89%)</td>
<td><strong>Employment:</strong></td>
</tr>
<tr>
<td><strong>Ethnicity:</strong></td>
<td>NR</td>
<td><strong>Method of administration:</strong></td>
</tr>
<tr>
<td><strong>Mean age:</strong></td>
<td>NR</td>
<td><strong>Needle sharing:</strong></td>
</tr>
<tr>
<td><strong>Outcomes and methods of analysis:</strong></td>
<td></td>
<td><strong>Sexual health:</strong></td>
</tr>
<tr>
<td><strong>Outcomes measured:</strong></td>
<td>steroid use, needle sharing and disposal, adverse effects, sources of information</td>
<td><strong>Impact of NSP on health and behaviour</strong></td>
</tr>
<tr>
<td><strong>How measured:</strong></td>
<td>Survey</td>
<td>Disposing of needles: most common methods included passing onto someone else (n=24), put them in a dustbin (n=26), NSP (n=18). Additionally n=3 disposed of them down a drain, n=3 left them lying around.</td>
</tr>
<tr>
<td><strong>Methods of analysis:</strong></td>
<td>descriptives</td>
<td><strong>Uptake of services</strong></td>
</tr>
<tr>
<td><strong>Length of follow-up:</strong></td>
<td>NA</td>
<td>States that “Further questioning revealed that... AS users perceived themselves as being different from stereotypical drug users. This clearly has implications for service provision for this client group”.</td>
</tr>
<tr>
<td><strong>Number of participants lost to follow-up:</strong></td>
<td>NA</td>
<td><strong>Accessing and reaching steroid users</strong></td>
</tr>
<tr>
<td><strong>Source of advice and information:</strong></td>
<td>57% friend or training partner; 11% gym owner; 28% books and magazines</td>
<td></td>
</tr>
</tbody>
</table>

NR=not reported; NA=not applicable
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Relevant findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day et al., 2008</td>
<td><strong>Entry criteria:</strong> Steroid injecting respondents among NSP Survey participants</td>
<td><strong>Profile of NSP clients</strong></td>
</tr>
<tr>
<td><strong>Country:</strong> Australia</td>
<td></td>
<td>Mean age 27 years; 16 (1%) homosexual or bisexual. More likely than other drug users to be male (OR 16.04, 8.54-30.15), younger (27 vs 30 years) and heterosexual (OR 3.70, 2.23-6.13).</td>
</tr>
<tr>
<td><strong>Objectives:</strong> To examine risk behaviours among steroid injectors</td>
<td><strong>Participant characteristics</strong></td>
<td>Steroid users are less likely to screen HCV positive (OR 0.10, 0.07-0.15); Steroid users are less likely to have risky injecting behaviour: needle sharing (OR 0.18, 0.09-0.36); daily or more frequent injecting (OR 0.14, 0.10-0.19). Steroid injectors less likely to report a history of screening for HCV (OR 0.17, 0-13-0.22) or HIV (OR 0.21, 0.17-0.26).</td>
</tr>
<tr>
<td><strong>Funding source:</strong> Australian Government Department of Health and Aging; National Health Medical Research Council Public Health Post-doctoral Fellowship</td>
<td><strong>Number of participants:</strong> 318</td>
<td><strong>Impact of NSP on health and behaviour</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Male (%):</strong> 306 (96%)</td>
<td><strong>NR</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Ethnicity:</strong> NR</td>
<td><strong>Uptake of services</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Mean age:</strong> 27 years</td>
<td><strong>NR</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Outcomes and methods of analysis</strong></td>
<td><strong>Accessing and reaching steroid users</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Outcomes measured:</strong> risky injecting behaviour, BBV prevalence</td>
<td><strong>NR</strong></td>
</tr>
<tr>
<td></td>
<td><strong>How measured:</strong> survey</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Methods of analysis:</strong> NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Length of follow-up:</strong> NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Number of participants lost to follow-up:</strong> NA</td>
<td></td>
</tr>
</tbody>
</table>

NR=not reported; NA=not applicable
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Relevant findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Korkia et al., 1996</td>
<td><strong>Entry criteria:</strong> Female anabolic steroid users recruited through gyms</td>
<td><strong>Profile of service users</strong></td>
</tr>
<tr>
<td><strong>Country:</strong> UK</td>
<td></td>
<td>Employment: 5 FT, 3 PT, 3 SE, 4 unemployed</td>
</tr>
<tr>
<td><strong>Objectives:</strong> To find out about patterns of steroid use amongst women, health effects and information about services that would be acceptable to them</td>
<td></td>
<td><strong>Impact of NSP on health and behaviour</strong></td>
</tr>
<tr>
<td><strong>Funding source:</strong> NR</td>
<td></td>
<td><strong>Uptake of services</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Two women received medical monitoring of steroid use – through GP and a private lab.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ideal service provision: information wanted – how to combat side effects, testing for</td>
</tr>
<tr>
<td></td>
<td></td>
<td>counterfeits, advice from a doctor and on safe yet effective dosages.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ideal service should cope with both health issues and efficacy of anabolic steroids – so</td>
</tr>
<tr>
<td></td>
<td></td>
<td>would involve a qualified doctor, health checks and also general advice about anabolic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>steroid dosage, administration and counterfeits.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suggested settings for service provision – local drugs centre, gyms.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8/15 would be prepared to pay for the service between £10-£20 a time.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Accessing and reaching steroid users</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Three most important sources of information were friends, anabolic steroid handbooks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and the gym manager</td>
</tr>
</tbody>
</table>

NR=not reported; NA=not applicable
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Relevant findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larance et al., 2008</td>
<td>Entry criteria: 17 years and older, had used anabolic substances for non-medical purposes in the past 6 months, resident in Sydney for past 12 months. Participants were recruited via advertisements through settings including NSP, internet forums and gyms.</td>
<td><strong>Profile of clients</strong>&lt;br&gt;Ever shared needles: 5%; shared in last month 2%&lt;br&gt;Ever re-used needles: 13%&lt;br&gt;Ever shared vial/bladder/container: 29%&lt;br&gt;BBV status: 3% HBV positive; 5% HCV positive; 12% HIV positive</td>
</tr>
<tr>
<td><strong>Country:</strong> Australia</td>
<td><strong>Participant characteristics</strong>&lt;br&gt;Number of participants: 60&lt;br&gt;Male (%): 60 (100%)&lt;br&gt;Ethnicity: NR&lt;br&gt;Mean age: 32 years</td>
<td><strong>Impact of NSP on health and behaviour</strong>&lt;br&gt;NR</td>
</tr>
<tr>
<td><strong>Objectives:</strong> To examine patterns of use, risk behaviours and related harm associated with PIEDs injections and the ways in which users seek injecting equipment and harm-reduction advice</td>
<td><strong>Outcomes and methods of analysis</strong>&lt;br&gt;Outcomes measured: patterns of PIED use, injecting behaviour, BBV status, correlates of risky injecting, information seeking and service utilisation&lt;br&gt;How measured: structured questionnaires through interview&lt;br&gt;Methods of analysis: descriptives, t-tests, Mann-Witney U test, OR, Fisher’s exact test, logistic regression analysis&lt;br&gt;Length of follow-up: NA&lt;br&gt;Number of participants lost to follow-up: NA</td>
<td><strong>Uptake of services</strong>&lt;br&gt;A significantly smaller proportion of gay/bisexual men report obtained equipment from NSP (39% vs 79%, p=&lt;.01)&lt;br&gt;Obtaining of needles and syringes from: NSP (71%), chemist/pharmacy (14%), doctor (11%), friend (2%), other (2%).</td>
</tr>
<tr>
<td><strong>Funding source:</strong> Australian Ministerial Council on Drug Strategy</td>
<td></td>
<td><strong>Accessing and reaching steroid users</strong>&lt;br&gt;Most common sources of information about PIEDs were internet sites (62%), friends (55%), doctor (22%), gym (18%).&lt;br&gt;Regular information seeking about PIEDs: 17% every day, 27% weekly or more, 26% 2-4 weeks, 23% every 6 months.</td>
</tr>
</tbody>
</table>

NR=not reported; NA=not applicable
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Relevant findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lenehan et al., 1996</td>
<td><strong>Entry criteria:</strong> Gym users</td>
<td><strong>Profile of service users</strong></td>
</tr>
<tr>
<td><strong>Country:</strong> UK</td>
<td><strong>Participant characteristics</strong></td>
<td>89% in employment; 2% in competitive sport</td>
</tr>
<tr>
<td><strong>Objectives:</strong> To provide detail on prevalence and patterns of steroid use in the North West of England</td>
<td><strong>Number of participants:</strong> n=386</td>
<td><strong>Impact of NSP on health and behaviour</strong></td>
</tr>
<tr>
<td><strong>Funding source:</strong> NR</td>
<td><strong>Male (%):</strong> n=379 (98%)</td>
<td><strong>Uptake of services</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Ethnicity:</strong> White 84%; 14% Afro-Caribbean, 2% Asian.</td>
<td>97% did not experience problems gaining access to injecting equipment</td>
</tr>
<tr>
<td></td>
<td><strong>Mean age:</strong> 28 years (17-56)</td>
<td>92% would attend a free NSP for steroid users</td>
</tr>
<tr>
<td></td>
<td><strong>Outcomes and methods of analysis</strong></td>
<td><strong>Accessing and reaching steroid users</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Outcomes measured:</strong> side effects, steroid use</td>
<td>22% had sought medical intervention for side effects GP (n=49), NSP (n=5), Hospital (n=4).</td>
</tr>
<tr>
<td></td>
<td><strong>How measured:</strong> Structured interviews</td>
<td>Acquired equipment from in order: gym owner, NSP, friends, dealer, chemist, trainer, doctor</td>
</tr>
<tr>
<td></td>
<td><strong>Methods of analysis:</strong> Descriptives</td>
<td><strong>Length of follow-up:</strong> NA</td>
</tr>
<tr>
<td></td>
<td><strong>Number of participants lost to follow-up:</strong> NA</td>
<td><strong>Number of participants lost to follow-up:</strong> NA</td>
</tr>
</tbody>
</table>

NR=not reported; NA=not applicable
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Relevant findings</th>
</tr>
</thead>
</table>
| Simmonds and Coomber, 2009 | **Entry criteria:** Injecting steroid users, recruited from gyms. The wider study included injecting drug users recruited from safer injecting facilities. | **Profile of NSP clients**
Higher rates of employment in comparison to other IDUs
They feel different from other injecting IDUs: do not want to be misconstrued as a "junkie" by health professionals or peers. Instead they perceive themselves as more ordinary as they do not experience dependence or withdrawal.
3 out of the 4 (75%) steroid users were employed. |
| **Country:** UK | **Participant characteristics**
Number of participants: n=91 (4 steroid users)
Male (%): n=66 (73%)
Ethnicity: n=87 (96%) white British
Mean age: 32 years | **Impact of NSP on health and behaviour**
NR |
| **Objectives:** examines the way that social stigma impact on IDU populations and within them, and the consequences for prevention and harm reduction | **Outcomes measured:** topics relating to stigma
**How measured:** interviews
**Methods of analysis:** thematic analysis | **Uptake of services**
Stigma a particular problem for AS users regarding NSP use – being recognised was a particular problem; were concerned about what others thought of them and did not wish to be seen as a “junkie” – keen to distance themselves from heroin users. |
| **Funding source:** NR | **Number of participants lost to follow-up:** NA | **Accessing and reaching steroid users**
Steroid users sceptical about involving gyms in needle exchange: “big fitness health clubs are not going to advertise the fact they allow steroid people to use their gyms but a lot of smaller ones would” |

NR=not reported; NA=not applicable
<table>
<thead>
<tr>
<th>Study details</th>
<th>Population and setting</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walker &amp; Joubert, 2011</td>
<td><strong>Entry criteria:</strong> English speaking injecting male steroid users aged 16+, registered at two NSP</td>
<td><strong>Profile of service users</strong> Age: 26-30 years most popular age group (37%); majority of participants aged 20-30 (61%)</td>
</tr>
<tr>
<td><strong>Country:</strong> UK</td>
<td><strong>Participant characteristics</strong></td>
<td><strong>Impact of NSP on health and behaviour</strong> NR</td>
</tr>
<tr>
<td><strong>Objectives:</strong> To gain understanding about the attitudes of AAS users towards the media and towards health information</td>
<td><strong>Number of participants:</strong> 41</td>
<td><strong>Uptake of services</strong> NR</td>
</tr>
<tr>
<td><strong>Funding source:</strong> NR</td>
<td><strong>Male (%):</strong> 41 (100%)</td>
<td><strong>Accessing and reaching steroid users</strong> 38 participants (93%) knew at least one other user; 17 (42%) knew between 10-12 users. 14 (34%) indicated they get steroids from someone at the gym, 30 (98%) trust their source.</td>
</tr>
<tr>
<td></td>
<td><strong>Ethnicity:</strong> Caucasian n=34 (83%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcomes and methods of analysis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcomes measured:</strong> steroid use; perceptions of media influence; health; gender constructs</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>How measured:</strong> survey</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Methods of analysis:</strong> descriptives</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Length of follow-up:</strong> NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Number of participants lost to follow-up:</strong> NA</td>
<td></td>
</tr>
</tbody>
</table>

NR=not reported; NA=not applicable
## Appendix 4. Quality Appraisal Checklist Tables

<table>
<thead>
<tr>
<th></th>
<th>Burton, 1996</th>
<th>Day et al., 2008</th>
<th>Korkia et al., 1996</th>
<th>Larance et al., 2008</th>
<th>Lenehan et al., 1996</th>
<th>Walker and Joubert, 2011</th>
<th>Simmonds and Coomber, 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
<td>CS</td>
<td>Qualitative</td>
</tr>
<tr>
<td>1.2</td>
<td>+</td>
<td>NR</td>
<td>NR</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Appropriate</td>
</tr>
<tr>
<td>1.3</td>
<td>+</td>
<td>+</td>
<td>NR</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Not sure</td>
</tr>
<tr>
<td>2.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Appropriate</td>
</tr>
<tr>
<td>2.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Not described</td>
</tr>
<tr>
<td>2.3</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Unclear</td>
</tr>
<tr>
<td>2.4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Not sure</td>
</tr>
<tr>
<td>2.5</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>Not sure/not reported</td>
</tr>
<tr>
<td>3.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Rich</td>
</tr>
<tr>
<td>3.2</td>
<td>++</td>
<td>NR</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Not reported</td>
</tr>
<tr>
<td>3.3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Convincing</td>
</tr>
<tr>
<td>3.4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Relevant</td>
</tr>
<tr>
<td>3.5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Adequate</td>
</tr>
<tr>
<td>4.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>4.2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Overall</td>
</tr>
<tr>
<td>4.3</td>
<td>+</td>
<td>NR</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>4.4</td>
<td>NA</td>
<td>++</td>
<td>NA</td>
<td>++</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>5.1</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>5.2</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

CS=cross sectional study; NR=not reported; NA=not applicable